

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against 202012/01 (B.1.1.7): an exploratory analysis of a randomi

Lancet, The

397, 1351-1362

DOI: [10.1016/s0140-6736\(21\)00628-0](https://doi.org/10.1016/s0140-6736(21)00628-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Third-Party Materials. , 2020, , 144-144.		0
2	Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?. Journal of Korean Medical Science, 2021, 36, e124.	1.1	64
3	An overview of current COVID-19 vaccine platforms. Computational and Structural Biotechnology Journal, 2021, 19, 2508-2517.	1.9	99
4	Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. SSRN Electronic Journal, 0, , .	0.4	7
6	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
7	Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune Escape. SSRN Electronic Journal, 0, , .	0.4	0
8	Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	7
10	SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet, The, 2021, 397, 952-954.	6.3	462
14	COVID-19 vaccines for low- and middle-income countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 447-456.	0.7	59
16	Profiles of current COVID-19 vaccines. Wiener Klinische Wochenschrift, 2021, 133, 271-283.	1.0	32
17	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. Anaesthesia, Critical Care & Pain Medicine, 2021, , 100867.	0.6	0
18	Pandemic moves and countermoves: vaccines and viral variants. Lancet, The, 2021, 397, 1326-1327.	6.3	29
21	SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. Microorganisms, 2021, 9, 793.	1.6	20
22	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet, The, 2021, 397, 1459-1469.	6.3	557
24	Status Report on COVID-19 Vaccines Development. Current Infectious Disease Reports, 2021, 23, 9.	1.3	56
29	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet, The, 2021, 397, 1725-1735.	6.3	658
30	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823.	6.0	309
32	Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2. Viruses, 2021, 13, 898.	1.5	4

#	ARTICLE	IF	CITATIONS
33	Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	38
35	Neutralization of VUII B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	38
39	Proliferation of SARS-CoV-2 B.1.1.7 Variant in Pakistan-A Short Surveillance Account. <i>Frontiers in Public Health</i> , 2021, 9, 683378.	1.3	4
41	Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in Sâ€glycoprotein, infectivity, reâ€infectivity, immune escape and vaccines activity. <i>Reviews in Medical Virology</i> , 2022, 32, e2270.	3.9	71
43	Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1507-1517.	4.6	129
44	Key Considerations for the Development of Safe and Effective SARSâ€CoVâ€2 Subunit Vaccine: A Peptideâ€Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
45	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
47	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
48	A Quantitative Benefitâ€Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy. <i>Vaccines</i> , 2021, 9, 618.	2.1	5
49	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
50	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83
51	Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. <i>Vaccines</i> , 2021, 9, 700.	2.1	29
55	Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide. <i>Osong Public Health and Research Perspectives</i> , 2021, 12, 139-148.	0.7	9
57	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
58	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	2.1	5
60	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S6-S18.	0.8	16
61	Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. <i>Nature Medicine</i> , 2021, 27, 1370-1378.	15.2	260
62	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <i>Scientific Reports</i> , 2021, 11, 11998.	1.6	17

#	ARTICLE	IF	CITATIONS
64	SARS-CoV-2 vaccination efficacy on hospitalisation and variants. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100874.	0.6	2
66	Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. <i>Vaccines</i> , 2021, 9, 673.	2.1	53
67	Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk. <i>Frontiers in Immunology</i> , 2021, 12, 708820.	2.2	17
68	Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3491-3494.	1.4	37
70	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
71	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. <i>Journal of Virology</i> , 2021, 95, e0020321.	1.5	35
72	Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses. <i>Frontiers in Medicine</i> , 2021, 8, 704719.	1.2	8
73	COVISHIELD (AZD1222) Vaccine effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study. <i>Medical Journal Armed Forces India</i> , 2021, 77, S264-S270.	0.3	45
75	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
77	Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	84
79	COVID-19 vaccines: concerns beyond protective efficacy and safety. <i>Expert Review of Vaccines</i> , 2021, 20, 1013-1025.	2.0	56
80	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq1 1 0.784314 rgBT ₉₄ /Overlook	2.1	94
81	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
82	COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses. <i>Mathematical Biosciences</i> , 2021, 337, 108614.	0.9	78
83	Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0085921.	1.8	82
84	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, .	2.8	42
85	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
86	Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ TÂcell reactivity in infected or vaccinated individuals. <i>Cell Reports Medicine</i> , 2021, 2, 100355.	3.3	490

#	ARTICLE	IF	CITATIONS
87	Optimal allocation of limited vaccine to control an infectious disease: Simple analytical conditions. <i>Mathematical Biosciences</i> , 2021, 337, 108621.	0.9	24
90	Symptom study app provides real-world data on COVID-19 vaccines. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 890-891.	4.6	3
91	Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
92	Efficacy of COVID-19 vaccines: From clinical trials to real life. <i>Therapie</i> , 2021, 76, 277-283.	0.6	30
93	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	1.9	30
94	Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. <i>Virology Journal</i> , 2021, 18, 154.	1.4	29
95	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 415-422.	1.3	13
96	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
97	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
100	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
101	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. <i>Clinical Infectious Diseases</i> , 2022, 74, 1208-1219.	2.9	64
102	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <i>Critical Care</i> , 2021, 25, 244.	2.5	186
103	Covid-19: Free rapid testing may end once most adults are fully vaccinated. <i>BMJ</i> , The, 2021, 374, n1760.	3.0	2
104	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. <i>Pain and Therapy</i> , 2021, 10, 1309-1330.	1.5	28
105	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
107	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
109	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 910.	2.1	50
110	Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis. <i>Lancet</i> , The, 2021, 398, 577-578.	6.3	49

#	ARTICLE	IF	CITATIONS
111	SARS-CoV-2 Vaccines: Where Are We Now?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3535-3543.	2.0	36
112	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. <i>EClinicalMedicine</i> , 2021, 38, 101010.	3.2	28
113	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
114	Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India. <i>Journal of Infection</i> , 2021, 83, 237-279.	1.7	43
116	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
117	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
118	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485.	2.1	190
119	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
120	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
122	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
123	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3459-3476.	1.1	179
124	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
125	Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	15
126	Asymmetric cross-strain protection for amphibians exposed to a fungal-metabolite prophylactic treatment. <i>Biology Letters</i> , 2021, 17, 20210207.	1.0	6
128	Sars-Cov-2 virus and vaccination; biological and statistical framework. <i>Expert Review of Vaccines</i> , 2021, 20, 1059-1063.	2.0	0
129	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
130	A review on the COVID-19: Facts and current situation. <i>NeuroPharmac Journal</i> , 0, , 180-191.	0.1	3
131	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57

#	ARTICLE	IF	CITATIONS
134	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. <i>Vaccines</i> , 2021, 9, 914.	2.1	20
135	Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0110521.	1.8	21
138	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290
139	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	5.8	22
140	Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. <i>Cancers</i> , 2021, 13, 4757.	1.7	10
141	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	2.5	39
142	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e627-e637.	2.2	132
144	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , 2021, 11, 1889-1903.	1.4	6
145	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
146	Letter to the editor: More data on vaccine efficacy/effectiveness of COVID-19 vaccines against asymptomatic SARS-CoV-2 infection. <i>Eurosurveillance</i> , 2021, 26, .	3.9	0
147	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. <i>Life Sciences</i> , 2021, 280, 119744.	2.0	11
148	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. <i>Science Immunology</i> , 2021, 6, eabl4509.	5.6	141
149	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 258-270.	2.7	27
150	Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. <i>The Lancet Regional Health Americas</i> , 2021, 4, 100065.	1.5	70
151	Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Stroke</i> , 2021, 52, 3045-3053.	1.0	38
153	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	13.9	734
154	Failures of quarantine systems for preventing COVID-19 outbreaks in Australia and New Zealand. <i>Medical Journal of Australia</i> , 2021, 215, 320-324.	0.8	47
155	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83

#	ARTICLE	IF	CITATIONS
156	Authors'™ response: Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: More data on asymptomatic SARS-CoV-2 infection. <i>Eurosurveillance</i> , 2021, 26, .	3.9	0
158	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	13.9	458
159	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
160	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
162	Shooting at a Moving Target™ Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
163	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
164	Why Does the SARS-CoV-2 Delta VOC Spread So Rapidly? Universal Conditions for the Rapid Spread of Respiratory Viruses, Minimum Viral Loads for Viral Aerosol Generation, Effects of Vaccination on Viral Aerosol Generation, and Viral Aerosol Clouds. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9804.	1.2	19
165	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
166	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
167	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2022, 33, 110-136.	1.9	4
168	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
170	Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. <i>Viruses</i> , 2021, 13, 1782.	1.5	70
171	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e52-e58.	4.6	59
173	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
174	Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies. <i>Journal of Molecular Biology</i> , 2021, 433, 167155.	2.0	53
177	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
178	Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Pathology Research and Practice</i> , 2021, 225, 153565.	1.0	8
179	Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5152-5160.	2.5	11

#	ARTICLE	IF	CITATIONS
180	Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. <i>EClinicalMedicine</i> , 2021, 39, 101064.	3.2	116
181	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 690621.	1.8	60
182	Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. <i>Vaccines</i> , 2021, 9, 989.	2.1	90
184	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	44
185	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
186	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
187	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003769.	3.9	83
188	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
189	Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 BA.1 617 2 Delta Variant Despite Reduced Virus Neutralisation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
190	The emerging SARS-CoV-2 variants of concern. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110243.	1.1	82
192	Role of artificial intelligence in peptide vaccine design against RNA viruses. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100768.	1.9	10
193	Adenoviral vector based platforms for developing effective vaccines to combat respiratory viral infections. <i>Clinical and Translational Immunology</i> , 2021, 10, e1345.	1.7	14
194	COVID-19 Vaccines: Adenoviral Vectors. <i>Annual Review of Medicine</i> , 2022, 73, 41-54.	5.0	46
195	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
196	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
197	Break Through Infection Following Covid 19 Vaccination Among Health Care Workers In South India .. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 25-26.	0.3	0
198	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
199	Near-Complete Genome of SARS-CoV-2 Delta (AY.3) Variant Identified in a Dog in Kansas, USA. <i>Viruses</i> , 2021, 13, 2104.	1.5	18

#	ARTICLE	IF	CITATIONS
200	Vaccine rollout strategies: The case for vaccinating essential workers early. PLOS Global Public Health, 2021, 1, e0000020.	0.5	25
201	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nature Communications, 2021, 12, 5868.	5.8	52
202	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus, 2021, 11, 20210008.	1.5	24
203	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Review of Vaccines, 2022, 21, 47-67.	2.0	3
205	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	5.8	38
206	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. Lancet Respiratory Medicine, 2021, 9, 1450-1466.	5.2	110
207	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines, 2021, 9, 1196.	2.1	15
208	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines, 2021, 9, 1195.	2.1	90
209	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 714170.	2.2	145
210	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates. Clinical Infectious Diseases, 2022, 75, e764-e773.	2.9	5
212	Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Nanomedicine, 2021, 16, 2377-2387.	1.7	8
213	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology, 2021, 101, 108232.	1.7	14
214	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. Life, 2021, 11, 1152.	1.1	5
215	Vaccine development and technology for SARS-CoV-2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
216	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949.	1.8	26
217	Sex and Gender in COVID-19 Vaccine Research: Substantial Evidence Gaps Remain. Frontiers in Global Women's Health, 2021, 2, 761511.	1.1	52
219	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. Immune Network, 2021, 21, e32.	1.6	51
220	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	1.7	63

#	ARTICLE	IF	CITATIONS
221	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
222	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
223	Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1899-1905.	2.9	15
224	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
225	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
227	ACE2â€™s S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2021, 2021, 1-10.	0.7	5
228	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50) randomised, controlled, phase 4 trial. <i>Lancet, The</i> , 2021, 398, 2277-2287.	6.3	83
229	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , 2021, 21, 2084.	1.2	30
230	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 473-482.	4.6	76
231	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. <i>Frontiers in Immunology</i> , 2021, 12, 772240.	2.2	33
232	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
233	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
234	Adenovirus vector-based vaccine for infectious diseases. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100432.	1.1	55
235	Vaccination against COVID-19 and societyâ€™s return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine-induced immunity. <i>BMJ Open</i> , 2021, 11, e053507.	0.8	10
236	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
237	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
238	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
239	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22

#	ARTICLE	IF	CITATIONS
240	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. <i>Vaccines</i> , 2021, 9, 1338.	2.1	17
241	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
242	The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. <i>Frontiers in Public Health</i> , 2021, 9, 775224.	1.3	156
243	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
244	Tracking and Controlling the Spatiotemporal Spread of SARS-CoV-2 Lineage B.1.1.7 in COVID-19 Reopenings. <i>GeoHealth</i> , 2021, 5, e2021GH000517.	1.9	7
245	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. <i>Nature</i> , 2022, 601, 617-622.	13.7	153
246	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 329-340.	4.6	103
247	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
248	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0258704.	1.1	12
249	Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 398-404.	2.8	90
250	A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2. <i>The Open Covid Journal</i> , 2021, 1, 117-138.	0.4	0
251	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152); interim results of a randomised, double-blind, controlled, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 2173-2184.	6.3	261
252	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
253	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. <i>PLoS ONE</i> , 2021, 16, e0258645.	1.1	13
255	Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 161-168.	3.6	147
257	Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study. <i>Frontiers in Public Health</i> , 2021, 9, 801763.	1.3	9
258	Caveats on COVID-19 herd immunity threshold: the Spain case. <i>Scientific Reports</i> , 2022, 12, 598.	1.6	8
259	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110368.	2.9	82

#	ARTICLE	IF	CITATIONS
260	Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	6
261	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
262	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
263	SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron. <i>Frontiers in Immunology</i> , 2022, 13, 801431.	2.2	31
264	The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. <i>Clinical and Molecular Allergy</i> , 2022, 20, 1.	0.8	15
265	Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach. <i>Journal of Medical Virology</i> , 2022, 94, 1670-1688.	2.5	6
266	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
267	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
270	Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective. <i>Human Vaccines and Immunotherapeutics</i> , 2022, , 1-3.	1.4	3
271	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. <i>Journal of Medical Virology</i> , 2022, 94, 2369-2375.	2.5	24
272	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
273	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
275	Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development. <i>Current Research in Structural Biology</i> , 2022, 4, 41-50.	1.1	25
276	High Incidence of SARS-CoV-2 Within Incarcerated Populations and Possible Implications for Herd Immunity. <i>Journal of Correctional Health Care</i> , 2022, , .	0.2	0
277	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
278	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194
279	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
280	Emerging Vaccine-Breakthrough SARS-CoV-2 Variants. <i>ACS Infectious Diseases</i> , 2022, 8, 546-556.	1.8	59

#	ARTICLE	IF	CITATIONS
281	Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. <i>Biosensors and Bioelectronics</i> , 2022, 204, 114067.	5.3	9
282	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2022, 19, 314-331.	6.1	46
283	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29
284	The effect of COVID-19 vaccination in Italy and perspectives for living with the virus. <i>Nature Communications</i> , 2021, 12, 7272.	5.8	40
285	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021, 6, 146.	2.9	14
286	Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 225, 1141-1150.	1.9	102
287	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ</i> , The, 2021, 375, e068848.	3.0	180
288	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
291	Interim statement on covid-19 vaccine booster doses. <i>Neurosciences</i> , 2021, 26, 403-405.	0.1	2
292	Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
293	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
294	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350.	2.1	44
295	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
296	Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature. <i>Cureus</i> , 2022, 14, e22669.	0.2	8
297	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
298	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	1
299	Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 61.	7.1	12
301	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96

#	ARTICLE	IF	CITATIONS
303	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
304	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
305	Assessment of the feasibility of pool testing for SARS-CoV-2 infection screening. <i>Infectious Diseases</i> , 2022, 54, 478-487.	1.4	1
306	SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?. <i>Vaccines</i> , 2022, 10, 444.	2.1	11
308	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
309	<sc>SARS-CoV-2</sc> vaccination and practical points in psoriasis patients: A narrative review. <i>Dermatologic Therapy</i> , 2022, 35, e15430.	0.8	6
310	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
311	The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. <i>Open Microbiology Journal</i> , 2022, 16, .	0.2	1
313	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
314	Clinical development and approval of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 609-619.	2.0	26
315	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
316	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	7
317	Identifying vaccine escape sites via statistical comparisons of short-term molecular dynamics. <i>Biophysical Reports</i> , 2022, 2, 100056.	0.7	2
318	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9
319	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1491-1500.	15.2	239
320	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
321	Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. <i>EClinicalMedicine</i> , 2022, 46, 101344.	3.2	7
322	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21

#	ARTICLE	IF	CITATIONS
323	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
324	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
325	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
326	Criteria for judging the immune markers of COVID-19 disease vaccines. <i>MedComm</i> , 2022, 3, 1-12.	3.1	3
327	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
328	COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study. <i>Vaccines</i> , 2022, 10, 17.	2.1	16
330	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
332	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
333	The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05028.	1.2	4
334	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
335	COVID-19 Vaccination Passports: Are They a Threat to Equality?. <i>Public Health Ethics</i> , 2022, 15, 51-63.	0.4	5
336	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
337	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
338	Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar. <i>BMC Public Health</i> , 2022, 22, 724.	1.2	9
339	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
340	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
341	Impact of Covishield Vaccination in Terms of SARS CoV-2 Neutralizing Antibody Expression. <i>Indian Journal of Clinical Biochemistry</i> , 2022, , 1-8.	0.9	0
342	New Frontier in Antiviral Drugs for Disorders of the Respiratory System. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, 2-12.	0.4	1

#	ARTICLE	IF	CITATIONS
343	Seroprevalence and dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination. <i>Epidemiology and Infection</i> , 2022, 150, 1-20.	1.0	9
344	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
345	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
346	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
347	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
348	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	0.9	6
349	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
350	Set-Valued Control to COVID-19 Spread with Treatment and Limitation of Vaccination Resources. <i>Iranian Journal of Science and Technology, Transaction A: Science</i> , 2022, , 1-10.	0.7	0
351	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. <i>Med</i> , 2022, 3, 406-421.e4.	2.2	17
352	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
353	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 38.	2.7	11
354	Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. <i>Journal of Neurology</i> , 2022, 269, 4000-4012.	1.8	9
355	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12
356	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
357	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. <i>Journal of Hematology and Oncology</i> , 2022, 15, 54.	6.9	26
358	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
359	New-Onset Acute Kidney Disease Post COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 742.	2.1	12
360	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153

#	ARTICLE	IF	CITATIONS
361	Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. <i>Pharmaceutics</i> , 2022, 14, 1066.	2.0	11
362	Predicting the Disease Severity of Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 111-139.	0.8	0
363	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
364	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
365	“Vaccinate every child against COVID-19” A scientific or socioeconomic need?. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 1658.	0.3	0
366	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
367	Monitoring of Adverse Events Associated with COVID-19 Vaccine (Tozinameran) -Influence of Sex, Age, and Number of Doses on the Frequencies of Adverse Reactions-. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2022, 96, 65-73.	0.0	1
368	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. <i>Russian Pediatric Journal</i> , 2022, 25, 139-146.	0.0	0
369	SARS-CoV-2 Non Responders - An Analysis of Non Responsiveness to SARS-CoV-2 Vaccines among Healthcare Workers in 2021. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	2
370	Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 81.	0.9	15
372	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
373	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ</i> , The, 0, , e069989.	3.0	78
374	Changing Dynamics of SARS-CoV-2: A Global Challenge. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5546.	1.3	3
375	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
376	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
377	First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India. <i>BMJ Global Health</i> , 2022, 7, e008271.	2.0	6
378	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
379	Antigenicity of genomic epidemiology concerning viral evolution and vaccine efficacy for SARS-COV-2- A review. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
380	ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. <i>Vaccines</i> , 2022, 10, 959.	2.1	3
381	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
382	Addressing COVID-19 vaccine hesitancy. <i>Drugs in Context</i> , 0, 11, 1-19.	1.0	11
383	Immune Response to SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1464.	1.4	24
384	COVID-19 Vaccination Hesitancy among Healthcare Workersâ€”A Review. <i>Vaccines</i> , 2022, 10, 948.	2.1	88
385	SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	12
386	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
387	Vaccination games in prevention of infectious diseases with application to COVID-19. <i>Chaos, Solitons and Fractals</i> , 2022, 161, 112294.	2.5	5
390	Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study. <i>BMJ Open</i> , 2022, 12, e057281.	0.8	1
391	Quantifying the COVID19 infection risk due to droplet/aerosol inhalation. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
392	The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
393	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 0, 11, .	2.8	7
394	COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913.	0.9	3
395	Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. <i>Pharmaceutics</i> , 2022, 14, 1432.	2.0	7
396	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
397	The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. <i>Therapie</i> , 2023, 78, 293-302.	0.6	1
398	EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 â€” AN OVERVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 6-16.	0.3	1
400	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
401	Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100296.	1.5	5
402	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
403	Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122042.	2.6	17
404	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. <i>International Journal of Biological Sciences</i> , 2022, 18, 4642-4647.	2.6	4
405	A Comprehensive Review on Efficacy and Adverse Events Associated With Different Covid-19 Vaccines. <i>Jordan Journal of Pharmaceutical Sciences</i> , 2022, 15, 289-304.	0.2	2
406	SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
407	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8485.	1.8	6
408	Efficacy and effectiveness of SARS-CoV-2 vaccines for death prevention: A protocol for a systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0265414.	1.1	2
409	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
410	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
411	Co-existence and co-infection of influenza A viruses and coronaviruses: Public health challenges. <i>Innovation(China)</i> , 2022, 3, 100306.	5.2	13
412	Estimating SARS-CoV-2 variant fitness and the impact of interventions in England using statistical and geo-spatial agent-based models. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2022, 380, .	1.6	7
414	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
415	Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
416	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	5.8	12
417	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
418	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
419	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23

#	ARTICLE	IF	CITATIONS
420	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
421	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
422	Emergence of COVID-19 Variants and Its Global Impact. , 2022, , 183-201.		1
423	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
424	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
425	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
426	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 2383-2392.	3.0	44
427	A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxisâ€”ICE-COVID. <i>Trials</i> , 2022, 23, .	0.7	4
429	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
430	Struktur Biomolekul dan Mekanisme Aksi Vaksin Sars-Cov-2 Efektif dalam Melawan Covid-19. , 2022, 2, 1-10.		0
431	Molecular modelling on multiepitope-based vaccine against SARS-CoV-2 using immunoinformatics, molecular docking, and molecular dynamics simulation. <i>SAR and QSAR in Environmental Research</i> , 2022, 33, 649-675.	1.0	3
432	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
433	Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
434	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELDâ„¢ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
435	Effectiveness of ChAdOx1 nCoV-19 coronavirus vaccine in preventing severe disease and mortality during the second wave of pandemic: A case-case analysis from a tertiary care center in South India. <i>Journal of Acute Disease</i> , 2022, 11, 188.	0.0	1
436	Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study. <i>Vaccines</i> , 2022, 10, 1706.	2.1	3
437	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
438	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1

#	ARTICLE	IF	CITATIONS
439	Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. <i>Science</i> , 2022, 378, .	6.0	141
440	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
442	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
443	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
444	How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	1
445	Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2. <i>MBio</i> , 2022, 13, .	1.8	4
446	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
447	Role of next-generation sequencing in diagnosing, tracking and vaccine development of severe acute respiratory syndrome coronavirus 2. <i>Journal of the Academy of Clinical Microbiologists</i> , 2022, 24, 25.	0.2	0
448	Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. <i>Biomedicines</i> , 2022, 10, 2892.	1.4	4
449	Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study. <i>BMJ Open</i> , 2022, 12, e063159.	0.8	3
450	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
451	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets. <i>Npj Vaccines</i> , 2022, 7, .	2.9	0
452	Auricular acupressure for adverse events following immunization after COVID-19 vaccine injection: A multicentre, blinded, randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2022, 71, 102900.	1.3	0
453	HEHR: Homing Endonuclease-Mediated Homologous Recombination for Efficient Adenovirus Genome Engineering. <i>Genes</i> , 2022, 13, 2129.	1.0	3
454	SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity. <i>Virus Evolution</i> , 2022, 8, .	2.2	4
455	Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology. <i>Vaccines</i> , 2022, 10, 2004.	2.1	17
457	Efficacy and Safety of COVID-19 Vaccines – An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
459	SARS-CoV-2 viral load and shedding kinetics. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	57

#	ARTICLE	IF	CITATIONS
460	Main Predictors of COVID-19 Vaccination Uptake among Italian Healthcare Workers in Relation to Variable Degrees of Hesitancy: Result from a Cross-Sectional Online Survey. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 419.	0.9	9
461	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
462	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. <i>Microbes and Infection</i> , 2023, 25, 105082.	1.0	5
463	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 212-222.	1.5	9
465	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
466	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. <i>Vaccines</i> , 2022, 10, 2111.	2.1	1
467	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. <i>Cell Reports Medicine</i> , 2023, 4, 100882.	3.3	10
468	Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12
469	Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
470	One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	16
471	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
473	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
474	Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. <i>Vaccines</i> , 2023, 11, 58.	2.1	5
476	Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection. , 2023, , 37-76.		0
478	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. <i>Trends in Molecular Medicine</i> , 2023, 29, 255-267.	3.5	17
479	Propagation of SARS-CoV-2 in a Closed Cell Culture Device: Potential GMP Compatible Production Platform for Live-Attenuated Vaccine Candidates under BSL-3 Conditions?. <i>Viruses</i> , 2023, 15, 397.	1.5	0
480	Epitope-directed anti-SARS-CoV-2 scFv engineered against the key spike protein region could block membrane fusion. <i>Protein Science</i> , 0, , .	3.1	1
481	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0

#	ARTICLE	IF	CITATIONS
482	Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
483	Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria. <i>Nature Communications</i> , 2023, 14, .	5.8	8
484	Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 956-964.	4.6	6
485	Efficacy of SARS-CoV-2 vaccines and the doseâ€“response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
486	Co-infection associated with SARS-CoV-2 and their management. <i>Future Science OA</i> , 2022, 8, .	0.9	5
487	Vaccine Breakthrough COVID-19 Outbreak in Section of a Hospital with 88% Attack Rate: Lessons to Be Learned. <i>Covid</i> , 2023, 3, 226-237.	0.7	1
488	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
490	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 545.	2.1	3
491	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
492	A prospective observational study to evaluate the safety of COVID-19 mRNA vaccines administered to Qatar Rehabilitation Institute patients. <i>Qatar Medical Journal</i> , 2023, 2023, .	0.2	0
493	Variants of SARS-CoV-2: Influences on the Vaccinesâ€™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
494	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
495	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, .	1.6	1
496	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. <i>Npj Vaccines</i> , 2023, 8, .	2.9	13
497	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. <i>BMC Clinical Pathology</i> , 2023, 16, 2632010X2311612.	0.7	3
498	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
499	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
500	Immunology of COVID-19. , 2024, , 52-71.		0

#	ARTICLE	IF	CITATIONS
501	COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. MedComm, 2023, 4, .	3.1	19
502	An assessment of the strategy and status of COVID-19 vaccination in India. Immunologic Research, 2023, 71, 565-577.	1.3	3
503	COVID-19 Anti-Vaccine Sentiments in Malaysia: Narratives of Comments from Facebook Post. Vaccines, 2023, 11, 834.	2.1	0
509	COVID-19 Vaccination in Persons with Diabetes: How they Work. Contemporary Endocrinology, 2023, , 195-206.	0.3	0
521	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
522	Development of practical techniques for simultaneous detection and distinction of current and emerging SARS-CoV-2 variants. Analytical Sciences, 0, , .	0.8	0
528	The Recent Development of Therapeutic Strategies Against COVID-19. , 2023, , 23-37.		0
533	(Re-)emerging viral zoonotic diseases at the human-animal environment interface. , 2024, , 93-111.		0